Holen Sie sich die Stockscreener-App
1.30
4.00%
0.05
Vorhandelsmarkt:
1.30
Schlusskurs vom Vortag:
$1.25
Offen:
$1.25
24-Stunden-Volumen:
687.33K
Relative Volume:
0.53
Marktkapitalisierung:
$221.47M
Einnahmen:
$4.71M
Nettoeinkommen (Verlust:
$-58.01M
KGV:
-1.5788
EPS:
-0.8234
Netto-Cashflow:
$-46.68M
1W Leistung:
+1.56%
1M Leistung:
+4.00%
6M Leistung:
+4.00%
1J Leistung:
+7.44%
1-Tages-Spanne:
$1.232
$1.33
1-Wochen-Bereich:
$1.21
$1.4444
52-Wochen-Spanne:
$0.9495
$1.70
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Firmenname
Lucid Diagnostics Inc
Sektor
Branche
Telefon
212 949 4319
Adresse
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.30 | 212.95M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Eingeleitet | BTIG Research | Buy |
| 2021-11-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Needham | Buy |
Lucid Diagnostics Inc Aktie (LUCD) Neueste Nachrichten
Lucid Diagnostics (NASDAQ: LUCD) seeks 100M-share authorization increase - Stock Titan
Needham Reiterates Lucid Diagnostics (LUCD) Buy Recommendation - MSN
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Needham Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛
Lucid Diagnostics Outperforms Pressure BioSciences in Key Metrics - National Today
Lucid Diagnostics (LUCD) CMO holds 650K shares including restricted stock - Stock Titan
Layoff Watch: Whats the MACD signal for Lucid Diagnostics Inc2026 Analyst Calls & Long Hold Capital Preservation Plans - baoquankhu1.vn
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 - Quantisnow
Fed Meeting: Is Lucid Diagnostics Inc stock forming a cup and handle2026 PreEarnings & Community Consensus Picks - baoquankhu1.vn
Dividend Watch: Can Lucid Diagnostics Inc be recession proofTrade Exit Report & Precise Swing Trade Alerts - baoquankhu1.vn
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Raises Target Price to $9 - Moomoo
Breakout Move: What is the next catalyst for Lucid Diagnostics Inc2026 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Lucid Diagnostics to Participate in Needham Healthcare Conference - National Today
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Lucid Diagnostics to Participate in Fireside Chat at Healthcare Conference - National Today
Lucid Diagnostics CEO to Participate in Healthcare Conference - Intellectia AI
Lucid Diagnostics Inc. $LUCD Shares Purchased by Aberdeen Group plc - MarketBeat
Lucid CEO to speak at Needham healthcare conference on April 16 - Stock Titan
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2025 Earnings Call Transcript - MSN
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Aug Action: Whats the MACD signal for Lucid Diagnostics Inc2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
LUCD PE Ratio & Valuation, Is LUCD Overvalued - Intellectia AI
Lucid Diagnostics Inc. (LUCD) stock price, news, quote and history - Yahoo Finance UK
PAVmed Appoints New Executive to Drive Medical Device Development - Intellectia AI
PAVmed appoints Joseph Virgilio as medical device chief By Investing.com - Investing.com Canada
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio - ChartMill
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update - MarketBeat
Dow Update: Can Lucid Diagnostics Inc be recession proof2026 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Lucid Diagnostics’ Earnings Call: Momentum Amid Cash Strain - The Globe and Mail
LUCD: BTIG Reiterates Buy Rating with $2.50 Price Target | LUCD Stock News - GuruFocus
Profit Review: Whats the MACD signal for Lucid Diagnostics Inc2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
PAVmed Reports 2025 Financial Results, Strengthens Capital Structure, and Expands Medical Device Portfolio Under New Leadership - Minichart
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat By Investing.com - Investing.com South Africa
Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from BTIG Research - MarketBeat
PAVmed (NASDAQ: PAVM) overhauls capital structure and reports 2025 results - Stock Titan
Lucid Diagnostics (LUCD) Earnings Transcript - AOL.com
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - MarketScreener
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat - Investing.com
Lucid Diagnostics Inc. (LUCD) reports Q4 loss, beats revenue estimates - MSN
Lucid Diagnostics non-GAAP adjusted loss hits USD 12.6M in Q4 2025 - Medical Buyer
Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen - MarketBeat
Valuation Update: What is the long term forecast for Lucid Diagnostics Inc stockQuarterly Trade Review & Stepwise Trade Execution Plans - baoquankhu1.vn
PAVmed (PAVM) outlines going concern risk, Nasdaq compliance and growth plans - stocktitan.net
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2025 Earnings Call Transcript - Insider Monkey
[EFFECT] Lucid Diagnostics Inc. SEC Filing - Stock Titan
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - StreetInsider
Lucid Diagnostics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-03-27 - Seeking Alpha
Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD) - The Globe and Mail
Lucid Diagnostics reports Q4 revenue of $1.5M, VA contract By Investing.com - Investing.com South Africa
Lucid Diagnostics signals expanded VA market access and 29% sequential test volume growth while targeting Medicare and commercial payer wins - msn.com
Finanzdaten der Lucid Diagnostics Inc-Aktie (LUCD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):